DMP-1 Inhibitors encompass a diverse array of compounds that share the ability to modulate the expression or function of Dentin Matrix Protein 1 (DMP-1), a protein principally involved in the mineralization of bone and dentin. These inhibitors can exert their effects through various mechanisms, many of which engage the metabolic pathways and cellular activities critical for the proper functioning of osteoblasts and odontoblasts. For instance, glucocorticoids such as dexamethasone can attenuate the expression of DMP-1 by influencing the differentiation pathways of these bone-forming cells. Similarly, bisphosphonates like alendronate might impact DMP-1 indirectly by inhibiting osteoclast-mediated bone resorption, which is intimately linked to bone formation processes. Tetracycline and its derivatives, known to chelate calcium ions, could alter the mineralization gradient, thereby influencing the role of DMP-1 in the biomineralization process.
Other members of this chemical class include compounds that affect systemic mineral homeostasis and bone cell function, such as sevelamer, which can modulate phosphate levels, and calcitonin, which may modulate osteoclast activity. Heavy metals like lead and cadmium, through their toxic effects, can disrupt the delicate balance of bone remodeling, possibly leading to a downregulation of DMP-1 as a consequence of osteoblast impairment. Immunosuppressants such as cyclosporine A are also considered part of this group due to their adverse effects on bone metabolism. Additionally, some of these inhibitors, like rosiglitazone, belong to the class of drugs that target nuclear receptors and influence adipocyte differentiation over osteoblastogenesis, which can result in reduced DMP-1 expression. Compounds that affect glucose metabolism or that have antibiotic properties, such as ciprofloxacin, round out this class by altering the extracellular matrix environment or cellular health, leading to compromised bone matrix protein expression. Collectively, these DMP-1 inhibitors can influence the biological function or expression of DMP-1 by engaging with a spectrum of biochemical and cellular pathways, reflecting the complex regulation of this protein in bone and dentin physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Glucocorticoid that may decrease DMP-1 expression by inhibiting osteoblast differentiation and function. | ||||||
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
Can suppress bone formation and potentially DMP-1 expression through its action on osteoblasts. | ||||||
Tetracycline | 60-54-8 | sc-205858 sc-205858A sc-205858B sc-205858C sc-205858D | 10 g 25 g 100 g 500 g 1 kg | $63.00 $94.00 $270.00 $417.00 $634.00 | 6 | |
Binds to calcium ions, which could interfere with the mineralization process involving DMP-1. | ||||||
Calcitonin, Salmon | 47931-85-1 | sc-201167 sc-201167A | 1 mg 5 mg | $154.00 $625.00 | 1 | |
May decrease osteoblast activity, leading to reduced DMP-1 expression. | ||||||
Lead(II) Acetate | 301-04-2 | sc-507473 | 5 g | $85.00 | ||
Interferes with bone metabolism and could inhibit DMP-1 expression due to toxic effects on bone cells. | ||||||
Cadmium chloride, anhydrous | 10108-64-2 | sc-252533 sc-252533A sc-252533B | 10 g 50 g 500 g | $56.00 $183.00 $352.00 | 1 | |
Negatively affects bone density and could downregulate the activity of bone matrix proteins like DMP-1. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Could suppress osteoblast proliferation and activity, potentially reducing DMP-1 expression. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
May have deleterious effects on bone metabolism, affecting DMP-1 expression. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, it can inhibit osteoblast differentiation, which may lead to decreased DMP-1 expression. | ||||||
D(+)Glucose, Anhydrous | 50-99-7 | sc-211203 sc-211203B sc-211203A | 250 g 5 kg 1 kg | $38.00 $198.00 $65.00 | 5 | |
High levels, as in uncontrolled diabetes, may impair osteoblast function and reduce expression of bone matrix proteins like DMP-1. | ||||||